| 1.36 -0.04 (-2.86%) | 08-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.81 | 1-year : | 2.11 |
| Resists | First : | 1.54 | Second : | 1.81 |
| Pivot price | 1.29  |
|||
| Supports | First : | 1.27 | Second : | 1.11 |
| MAs | MA(5) : | 1.39 |
MA(20) : | 1.27 |
| MA(100) : | 1.34 |
MA(250) : | 1.28 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 61.7 |
D(3) : | 73.3 |
| RSI | RSI(14): 55.3 |
|||
| 52-week | High : | 2.34 | Low : | 0.76 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ALLR ] has closed below upper band by 33.7%. Bollinger Bands are 11.1% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.42 - 1.43 | 1.43 - 1.44 |
| Low: | 1.24 - 1.25 | 1.25 - 1.25 |
| Close: | 1.35 - 1.36 | 1.36 - 1.37 |
Allarity Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new cancer treatments. They utilize a unique "drug response predictor" technology to generate specific companion diagnostics, aiming to identify which patients will best respond to their various oncology therapeutics. The company's portfolio of investigational drugs for various cancers includes: Stenoparib: A poly-ADP-ribose polymerase (PARP) inhibitor currently in Phase 2 clinical trials for ovarian cancer. Dovitinib: A pan-tyrosine kinase inhibitor designed to treat renal cell carcinoma. IXEMPRA: A microtubule inhibitor used in the treatment of metastatic breast cancer. LiPlaCis: A liposomal formulation of cisplatin, undergoing Phase 2 clinical trials for metastatic breast cancer. 2X-111: A liposomal formulation of doxorubicin, also in Phase 2 studies for both metastatic breast cancer and glioblastoma multiforme. Established in 2004, Allarity Therapeutics maintains its headquarters in Cambridge, Massachusetts.
Wed, 22 Jul 2026
Are Medical Stocks Lagging Allarity Therapeutics, Inc. (ALLR) This Year? - Yahoo Finance
Mon, 06 Jul 2026
Is Allarity Therapeutics, Inc. (ALLR) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Wed, 01 Jul 2026
Allarity Therapeutics (NASDAQ: ALLR) wins key DRP patent and secures shareholder backing - Stock Titan
Tue, 30 Jun 2026
Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic - GlobeNewswire
Fri, 26 Jun 2026
ALLR Forecast — Price Target — Prediction for 2027 - TradingView
Thu, 18 Jun 2026
Allarity Therapeutics to Present Trial-in-Progress Poster - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 1.561e+007 (%) |
| Held by Institutions | 4.1 (%) |
| Shares Short | 175 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -10 % |
| Return on Assets (ttm) | 752 % |
| Return on Equity (ttm) | -23.8 % |
| Qtrly Rev. Growth | 345000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -172.4 |
| EBITDA (p.s.) | 676471 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 1.57 |
| Dividend | 0 |
| Forward Dividend | 145810 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|